Don’t Do It Alone: To De-Risk Your Next Trial, Seek Outside Expertise

March 28, 2019 Lakshmi Sundar

Whether the focus is endpoint adjudication, aggregate data monitoring or safety assessment, the clinical and device development industry clearly understands the value of establishing expert scientific committees to provide oversight on study data. These expert committee assessments provide validation on clinical data as additional support for regulatory submissions and commercial strategy. What is less well understood, however, is the importance of independent expertise. Without independent expertise, sponsors risk biased decision-making, conflicts of interest, potential clinical delays and squandered resources that could otherwise be avoided.

About the Author

Lakshmi Sundar

Lakshmi Sundar is the Head of Business Transformation at WCG ACI Clinical.

Follow on Linkedin More Content by Lakshmi Sundar
Previous Flipbook
Quality First: Using Data to Inform Site Selection in CNS
Quality First: Using Data to Inform Site Selection in CNS

WCG MedAvante-ProPhase espouses a rather simple philosophy: minimize variability, generate cleaner data.

Next Flipbook
Protecting Sponsors Against Bias and Variability
Protecting Sponsors Against Bias and Variability

Applied Clinical Trials recently spoke with Mark Opler, PhD, MPH, chief research officer of WCG, MedAvante-...

Request a Genetics in Clinical Trials training session

What You'll Learn